Total Trials provides specialized support for a broad range of therapeutic areas in clinical research.
Total Trials has extensive experience across the world’s leading global health priorities, including tuberculosis, HIV/AIDS, malaria, COVID-19 and other respiratory infectious diseases. Our expertise also extends to emerging and epidemic threats such as Ebola, Lassa fever, Nipah virus, Zika virus, Dengue fever, Chikungunya and Japanese encephalitis, as well as neglected tropical diseases including Onchocerciasis, Schistosomiasis, and Hookworm. This breadth reflects our experience supporting complex clinical research in both established public health programmes and rapidly evolving global health emergencies.
Hover over or tap a segment to see the number of studies. Click a category to expand it.
While Total Trials is recognised for its strengths in vaccines and global health, our experience extends across a broad range of therapeutic areas. We have supported clinical research in cardiometabolic disease, oncology, immunology, neurology, dermatology, women’s health, gastroenterology, musculoskeletal disorders, rare diseases, and other specialist indications. This breadth enables us to apply the operational expertise developed in complex global health programmes to a diverse portfolio of commercial clinical research.
The therapeutic areas shown represent our principal areas of experience. Our broader portfolio also includes ophthalmology, psychiatry, nephrology and urology, reproductive medicine, endocrinology, and other specialist indications.
Our vaccine portfolio spans the full clinical development lifecycle, from First in Human studies through Phase IV and post marketing research. It includes adult and paediatric populations, preventive and therapeutic vaccines, and research across infectious diseases, respiratory pathogens, and emerging global health priorities. Beyond the indications shown, Total Trials has also supported vaccine studies in diseases such as Lassa fever, Zika virus, HPV, polio, and paediatric combination immunisation programmes, reflecting broad expertise across diverse vaccine platforms and development programmes.
Our respiratory experience extends across infectious respiratory diseases, chronic respiratory conditions, and respiratory vaccine programmes. In addition to tuberculosis, COVID-19, influenza, RSV, pneumonia, and asthma, Total Trials has supported studies in COPD, pneumococcal disease, acute respiratory infections, nasal polyps, and multidrug resistant tuberculosis, providing experience across both communicable and chronic respiratory disease research.
We specialize in both solid tumors and hematologic oncology in early phase development, delivering comprehensive research support. Our global footprint enables us to conduct oncology studies wherever they are most advantageous. We support clients from IND planning through proof of concept, ensuring strategic and effective study execution.
Have questions or need more information? Reach out to our team—we’re here to help and eager to connect.
We envision a world where advances in vaccines and medicines help all people live longer, healthier lives.
